Sina Tebi, MD
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1437380789
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,601 of the $132,912 with a category attached, or 62.1%. 54 manufacturers reported payments, led by Lilly USA, LLC at 37.4% of the total. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,746 payments — averaging $76.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$50K
- Boehringer Ingelheim$21K
- Sanofi-aventis U.S. LLC$13K
- Corcept Therapeutics$10K
- Mannkind Corporation$9K
- Ascendis Pharma Endocrinology Inc$7K
- plus $23K from 48 others
Across 240 payments — averaging $9685.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.6M
- AbbVie$453K
- Novartis$217K
- Modernatx, Inc.$53K
- Sanofi US Services Inc.$23K
- Novo Nordisk AS$5K
What the payments were for
- Consulting fees$9,8807%
- Speaking & faculty fees$82,60162%
- Travel & lodging$3,6393%
- Food & beverage$36,21127%
- Education$5820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$30,733
- JARDIANCE$26,476
- Korlym$8,902
- AFREZZA$6,759
- TOUJEO$5,477
- SOLIQUA 100/33$3,184
- DISEASE STATE$2,655
- Yorvipath$1,989
- DEXCOM G6 TRANSMITTER$1,389
- LYUMJEV$1,300
- FREESTYLE LIBRE 3$438
- FreeStyle Libre 2$374
- Omnipod$330
- FARXIGA$250
- EVENITY$246
- Kerendia$220
- TZIELD$141
- MINIMED 780G$138
- Vascepa$125
- RYBELSUS$125
How this compares
$132,912 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 465 | $544,890 |
| JardianceEmpagliflozin | 355 | $404,052 |
| MounjaroTirzepatide | 259 | $287,025 |
| TrulicityDulaglutide | 217 | $284,230 |
| KorlymMifepristone | 13 | $262,210 |
| FarxigaDapagliflozin Propanediol | 137 | $138,410 |
| RybelsusSemaglutide | 67 | $137,703 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 110 | $120,621 |
| GlyxambiEmpagliflozin/Linagliptin | 80 | $112,393 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $111,094 |
| JanuviaSitagliptin Phosphate | 86 | $95,243 |
| TradjentaLinagliptin | 90 | $74,807 |
| ForteoTeriparatide | 17 | $67,702 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $44,210 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 101 | $43,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $4,740 | $682,593532 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $49,756 | $643,166523 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy | $20,878 | $604,411537 claims |
| Corcept TherapeuticsKorlym | $10,454 | $262,21013 claims |
| MerckJanuvia, Janumet Xr, Janumet | $349 | $143,689146 claims |
| AstraZenecaFarxiga | $1,732 | $138,410137 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $13,254 | $120,621110 claims |
| AmgenProlia | $1,467 | $32,64120 claims |
| BayerKerendia | $1,139 | $28,35726 claims |
| AbbVieSynthroid | $339 | $8,45483 claims |
| GSKTrelegy Ellipta | $36 | $8,37313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Anthony HeaneyLos Angeles$588K
- Christian GastelumLos Angeles$321K
- Shlomo MelmedLos Angeles$177K
- Glenn BraunsteinLos Angeles$113K
- Laurence KatznelsonLos Angeles$99K
- John CarmichaelLos Angeles$90K
- Peter ButlerLos Angeles$58K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.